CD9 expression indicates a poor outcome in acute lymphoblastic leukemia.

OBJECTIVE We undertook a single-center retrospective study to determine the relationship between CD9 and acute lymphoblastic leukemia (ALL). MATERIALS AND METHODS In total, 112 newly diagnosed patients in our center were enrolled in the study. Their clinical information was collected and the patients werefollowed over the course of the study. Flow cytometry was used to detect the expression of CD9. RESULTS CD9 expression was more common in B cell acute lymphoblastic leukemia (B-ALL) and patients > 40 years old. CD9-positive patients exhibited a higher BCR-ABL fusion gene positive rate and higher neutrophil counts than CD9 negative patients (P= 0.004 and P= 0.004, respectively). Response to induction chemotherapy was not dependent on CD9 expression. CD9-positive patients had a lower 2-year overall survival rate than CD9-negative patients. CONCLUSION CD9 expression predicts some clinical characteristics and indicates an unfavorable prognosis in ALL patients.

[1]  P. Saftig,et al.  The Emerging Role of Tetraspanins in the Proteolytic Processing of the Amyloid Precursor Protein , 2016, Front. Mol. Neurosci..

[2]  Y. Bae,et al.  CD9 Expression in Colorectal Carcinomas and Its Prognostic Significance , 2016, Journal of pathology and translational medicine.

[3]  Dengju Li,et al.  Prognosis of Patients With de novo Acute Myeloid Leukemia Resistant to Initial Induction Chemotherapy , 2016, The American journal of the medical sciences.

[4]  L. Jennings,et al.  The utility of tetraspanin CD9 as a biomarker for metastatic clear cell renal cell carcinoma. , 2016, Biochemical and biophysical research communications.

[5]  Qingyuan Zhang,et al.  The Expression of CD9 and PIK3CD is Associated with Prognosis of Follicular Lymphoma , 2015, Journal of Cancer.

[6]  K. Oritani,et al.  Novel CD9-targeted therapies in gastric cancer. , 2015, World journal of gastroenterology.

[7]  D. Corbeil,et al.  Tetraspanin CD9 determines invasiveness and tumorigenicity of human breast cancer cells , 2015, Oncotarget.

[8]  Atsushi Hijikata,et al.  Identification of CD34+ and CD34- leukemia-initiating cells in MLL-rearranged human acute lymphoblastic leukemia. , 2015, Blood.

[9]  S. Iwata,et al.  Regulation of cancer stem cell properties by CD9 in human B-acute lymphoblastic leukemia. , 2011, Biochemical and biophysical research communications.

[10]  L. Jennings,et al.  Tetraspanins and tumor progression , 2011, Clinical & Experimental Metastasis.

[11]  Chi-kong Li,et al.  The tetraspanin CD9 regulates migration, adhesion, and homing of human cord blood CD34+ hematopoietic stem and progenitor cells. , 2011, Blood.

[12]  C. Bloomfield,et al.  The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. , 2009, Blood.

[13]  S. Iwata,et al.  CD9 correlates with cancer stem cell potentials in human B-acute lymphoblastic leukemia cells. , 2009, Biochemical and biophysical research communications.

[14]  P. Atadja,et al.  Epigenetic Silencing of the Tetraspanin CD9 during Disease Progression in Multiple Myeloma Cells and Correlation with Survival , 2008, Clinical Cancer Research.

[15]  Jean Mosser,et al.  Five distinct biological processes and 14 differentially expressed genes characterize TEL/AML1-positive leukemia , 2007, BMC Genomics.

[16]  G. Superti-Furga,et al.  The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib , 2007, Proceedings of the National Academy of Sciences.

[17]  J. Delaissé,et al.  Endothelial cell-driven regulation of CD9 or motility-related protein-1 expression in multiple myeloma cells within the murine 5T33MM model and myeloma patients , 2006, Leukemia.

[18]  A. Órfão,et al.  Aberrant expression of tetraspanin molecules in B-cell chronic lymphoproliferative disorders and its correlation with normal B-cell maturation , 2005, Leukemia.

[19]  Jessica M. Lindvall,et al.  Gene expression profile of B cells from Xid mice and Btk knockout mice , 2004, European journal of immunology.

[20]  N. Varin‐Blank,et al.  CD9, a key actor in the dissemination of lymphoblastic leukemia, modulating CXCR4-mediated migration via RAC1 signaling. , 2015, Blood.